Ascelia Pharma provided a follow-up update yesterday, July 12, on the Complete Response Letter received on July 3. This is the first substantive detail the company has disclosed on the nature of the FDA's clinical concerns since the CRL, and it meaningfully narrows, though does not close, the range of scenarios we flagged in our July 3 note.

According to the company, it views the FDA's clinical concerns as related to the image reading process in the pivotal SPARKLE study (ASC-Man-P016), rather than to the underlying trial data itself. Ascelia states that issues in the initial image reading meant no efficacy conclusions could be drawn from the original readers' scoring, a point it says was previously disclosed. In response, the company implemented a new image reading process using independent, blinded readers with no prior knowledge of the SPARKLE images or the original results, conducted under predefined procedures. Ascelia further states that this remediation approach was discussed with the FDA and that the agency's feedback was incorporated into the NDA submission. Separately, the company notes that some of the FDA's remaining questions relate to product documentation, which it expects to address in the near term.

Set against our July 3 framing, this update points toward the milder end of the spectrum we described for the clinical component specifically: a methodology and interpretation issue on an already-completed pivotal trial, rather than a request for an entirely new clinical dataset. That is a meaningfully better starting point than the more severe scenario, since it does not, on its face, describe a failed endpoint or a data gap that only a new trial could fill.

Two things temper how reassuring this should be taken to be. First, this is Ascelia's own characterization of the FDA's concerns, not FDA's language or a confirmed resubmission classification, and companies naturally frame open regulatory issues in the most favorable light available to them. Second, and more importantly, the sequence itself raises a question: the company states the re-read methodology was already discussed with the FDA and that feedback was incorporated before the NDA was submitted, yet the FDA still issued a CRL. That suggests the FDA's concerns may extend beyond the re-read exercise Ascelia has already completed, whether around the independence or adequacy of that re-read, the consistency between the two reading rounds, or another aspect not yet disclosed. In other words, prior FDA engagement on this point did not prevent the CRL, which is worth keeping in mind before reading this update as a resolution.

What remains unaddressed is largely the same as before: there is still no indication of whether any eventual resubmission would be classified as Class 1 or Class 2, no confirmed timeline or date for the Type A meeting itself, and no update to the cash runway guidance or the potential partnership process. Ascelia has said it will provide a further update after the Type A meeting and receipt of the official meeting minutes, which remains the key event to watch.

It is also worth noting the range of views already published by other analysts covering the stock. ABG Sundal Collier's July 3 note left the stock unrated and suspended its valuation entirely pending clarity, citing the wide range of possible outcomes. DNB Carnegie, by contrast, set an explicit revised probability of Orviglance reaching the market of 50% (down from 85% previously) alongside a fair value range of SEK 0.4 to 2.0, having raised its WACC to 20%, removed near-term partner revenues, and pushed back the assumed launch by a year. That 50% figure sits well above the roughly 10% market-implied PoS we highlighted in our own July 3 note (around 8% with the current shareprice), underlining how differently professional analysts are currently weighing the same limited information.

Net, yesterday's update is incremental and directionally net positive for the clinical narrative, but it does not resolve the central uncertainty. We continue to await the Type A meeting, and specifically FDA's own characterization of the deficiencies and any resubmission classification, before updating our investment case.

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. Michael Friis, 07:45, 13/07-2026.